1/5/24 16:51 | 1/3/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S | -566 | 29.46 | 0 | -19 | -2 | 905 | D | | | | | | | | | | | | | | |
1/3/24 17:30 | 1/1/24 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 0 | 0.00 | 0 | 8 | 1 | 924 | D | | | | | | | | | | | | | | |
1/6/23 17:32 | 1/4/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S | -248 | 37.21 | 0 | -7 | -1 | 825 | D | | | | | | | | | | | | | | |
1/4/23 20:36 | 1/1/23 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 0 | 0.00 | 0 | 8 | 1 | 832 | D | | | | | | | | | | | | | | |
3/4/22 21:07 | 1/1/22 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 0 | 0.00 | 0 | 8 | 1 | 824 | D | | | | | | | | | | | | | | |
3/4/22 21:07 | 1/1/22 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.d | -280 | 112.26 | 0 | -2 | 0 | 824 | D | | | | | | | | | | | | | | |
9/1/21 20:21 | 8/30/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.dm | 2,071 | 17.06 | 0 | 121 | 18 | 778 | D | | | | | | | | | | | | | | |
9/1/21 20:21 | 8/30/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.dm | -19,520 | 160.83 | 0 | -121 | -13 | 778 | D | | | | | | | | | | | | | | |
8/25/21 16:14 | 8/23/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 364 | 13.40 | 0 | 27 | 4 | 778 | D | | | | | | | | | | | | | | |
8/25/21 16:14 | 8/23/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.d | -4,125 | 152.01 | 0 | -27 | -3 | 778 | D | | | | | | | | | | | | | | |
8/20/21 18:14 | 8/19/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 304 | 13.40 | 0 | 23 | 3 | 778 | D | | | | | | | | | | | | | | |
8/20/21 18:14 | 8/19/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.d | -3,431 | 151.28 | 0 | -23 | -3 | 778 | D | | | | | | | | | | | | | | |
4/15/21 20:50 | 4/13/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 290 | 11.16 | 0 | 26 | 3 | 778 | D | | | | | | | | | | | | | | |
4/2/21 20:46 | 4/1/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 1,005 | 14.15 | 0 | 71 | 10 | 752 | D | | | | | | | | | | | | | | |
4/2/21 20:46 | 4/1/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.d | -3,196 | 83.64 | 0 | -38 | -5 | 752 | D | | | | | | | | | | | | | | |
2/9/21 20:36 | 2/5/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.dm | 923 | 9.55 | 0 | 97 | 16 | 719 | D | | | | | | | | | | | | | | |
2/9/21 20:36 | 2/5/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.dm | -3,655 | 71.70 | 0 | -51 | -7 | 719 | D | | | | | | | | | | | | | | |
2/3/21 21:39 | 2/1/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.dm | 4,807 | 15.16 | 0 | 317 | 89 | 673 | D | | | | | | | | | | | | | | |
2/3/21 21:39 | 2/1/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.dm | -11,955 | 67.26 | 0 | -178 | -21 | 673 | D | | | | | | | | | | | | | | |
1/5/21 21:24 | 12/31/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 0 | 0.00 | 0 | 14 | 3 | 534 | D | | | | | | | | | | | | | | |
1/5/21 21:24 | 1/5/21 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.d | -349 | 55.86 | 0 | -6 | -1 | 534 | D | | | | | | | | | | | | | | |
11/27/20 21:00 | 11/27/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 566 | 16.17 | 0 | 35 | 7 | 526 | D | | | | | | | | | | | | | | |
11/27/20 21:00 | 11/27/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.d | -1,350 | 38.57 | 0 | -35 | -6 | 526 | D | | | | | | | | | | | | | | |
11/25/20 20:02 | 11/25/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 342 | 6.83 | 0 | 50 | 11 | 526 | D | | | | | | | | | | | | | | |
11/25/20 20:02 | 11/25/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.d | -1,800 | 36.00 | 0 | -50 | -9 | 526 | D | | | | | | | | | | | | | | |
11/18/20 19:56 | 11/16/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 292 | 14.58 | 0 | 20 | 4 | 526 | D | | | | | | | | | | | | | | |
11/18/20 19:56 | 11/16/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.d | -680 | 34.00 | 0 | -20 | -4 | 526 | D | | | | | | | | | | | | | | |
11/6/20 16:38 | 11/4/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 342 | 6.83 | 0 | 50 | 11 | 526 | D | | | | | | | | | | | | | | |
11/6/20 16:38 | 11/4/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.d | -1,300 | 26.00 | 0 | -50 | -9 | 526 | D | | | | | | | | | | | | | | |
10/9/20 16:14 | 10/7/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | M.d | 34 | 6.83 | 0 | 5 | 1 | 526 | D | | | | | | | | | | | | | | |
10/9/20 16:14 | 10/7/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | S.d | -109 | 21.83 | 0 | -5 | -1 | 526 | D | | | | | | | | | | | | | | |
9/3/20 16:15 | 9/1/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M. | MA | DO | P,CEO | M.d | 34 | 6.83 | 0 | 5 | 1 | 526 | D | | | | | | | | | | | | | | |
9/3/20 16:15 | 9/1/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M. | MA | DO | P,CEO | S.d | -109 | 21.83 | 0 | -5 | -1 | 526 | D | | | | | | | | | | | | | | |
8/7/20 19:29 | 8/6/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M. | MA | DO | P,CEO | M.d | 34 | 6.83 | 0 | 5 | 1 | 526 | D | | | | | | | | | | | | | | |
8/7/20 19:29 | 8/6/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M. | MA | DO | P,CEO | S.d | -109 | 21.83 | 0 | -5 | -1 | 526 | D | | | | | | | | | | | | | | |
7/2/20 16:10 | 7/1/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M. | MA | DO | P,CEO | M.d | 34 | 6.83 | 0 | 5 | 1 | 526 | D | | | | | | | | | | | | | | |
7/2/20 16:10 | 7/1/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M. | MA | DO | P,CEO | S.d | -109 | 21.83 | 0 | -5 | -1 | 526 | D | | | | | | | | | | | | | | |
6/5/20 17:18 | 6/3/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M. | MA | DO | P,CEO | M.d | 34 | 6.83 | 0 | 5 | 1 | 526 | D | | | | | | | | | | | | | | |
6/5/20 17:18 | 6/3/20 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M. | MA | DO | P,CEO | S.d | -109 | 21.83 | 0 | -5 | -1 | 526 | D | | | | | | | | | | | | | | |
12/26/19 16:33 | 12/20/19 | IQV | Iqvia Holdings Inc. | NC | Health | Biolab | Commercial Physical & Biologi | Leonard John M. | CT | D | | M.d | 1,308 | 64.77 | 0 | 20 | | 8 | D | | | | | | | | | | | | | | |
12/26/19 16:33 | 12/20/19 | IQV | Iqvia Holdings Inc. | NC | Health | Biolab | Commercial Physical & Biologi | Leonard John M. | CT | D | | S.d | -3,091 | 153.00 | 0 | -20 | -71 | 8 | D | | | | | | | | | | | | | | |
5/15/18 20:43 | 5/14/18 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M. | MA | DO | P,CEO | S | -202 | 24.00 | 0 | -8 | -2 | 526 | I | | | | | | | | | | | | | | |
9/16/16 18:46 | 9/15/16 | CMRX | Chimerix Inc | DE | Health | Drug | Pharmaceutical Preparations | Leonard John M. | NC | D | | S | -25 | 5.03 | 3 | -5 | -100 | 0 | I | -80 | -89 | 3 | 35 | 25 | 16 | 6 | 8 | 0 | 4 | -20 | -20 | 11 | |
8/25/15 14:25 | 8/21/15 | CMRX | Chimerix Inc | DE | Health | Drug | Pharmaceutical Preparations | Leonard John M. | NC | D | | P | 47 | 47.38 | 20 | 1 | 25 | 5 | I | 150 | 88 | 9 | 6 | -7 | -20 | -12 | -12 | 3 | 9 | -1 | -9 | -89 | -89 |
11/6/14 16:50 | 11/5/14 | CMRX | Chimerix Inc | DE | Health | Drug | Pharmaceutical Preparations | Leonard John M. | NC | D | | P | 116 | 29.00 | 33 | 4 | New | 4 | D | | 96 | 80 | 26 | 2 | -18 | -9 | -6 | 3 | 14 | 28 | 25 | 23 | 36 |
3/19/13 17:13 | 3/15/13 | ABBV | Abbvie Inc. | DE | Health | Drug | Pharmaceutical Preparations | Leonard John M. | IL | O | SVP,Chie | M.d | 1,348 | 28.86 | 33 | 47 | 70 | 114 | D | | | | | 2 | 3 | 2 | 3 | 2 | 3 | 11 | 13 | 22 | 44 |
3/19/13 17:13 | 3/15/13 | ABBV | Abbvie Inc. | DE | Health | Drug | Pharmaceutical Preparations | Leonard John M. | IL | O | SVP,Chie | S.d | -1,796 | 38.45 | 33 | -47 | -29 | 114 | D | | | | | 2 | 3 | 2 | 3 | 2 | 3 | 11 | 13 | 22 | 44 |
3/12/13 17:08 | 3/8/13 | ABBV | Abbvie Inc. | DE | Health | Drug | Pharmaceutical Preparations | Leonard John M. | IL | O | SVP,Chie | S | -1,048 | 37.51 | 33 | -28 | -20 | 114 | D | | | | | 2 | -1 | 2 | 0 | 0 | 3 | 17 | 19 | 21 | 44 |
2/21/13 17:04 | 2/19/13 | ABBV | Abbvie Inc. | DE | Health | Drug | Pharmaceutical Preparations | Leonard John M. | IL | O | SVP,Chie | M.d | 809 | 27.29 | 33 | 30 | 24 | 155 | D | | | | | 16 | 5 | 7 | 6 | -1 | -5 | -1 | 21 | 13 | 39 |